ES2429097T3 - Dispersión sólida que comprende un principio activo de bajo punto de fusión y comprimido para administración oral que la comprende - Google Patents

Dispersión sólida que comprende un principio activo de bajo punto de fusión y comprimido para administración oral que la comprende Download PDF

Info

Publication number
ES2429097T3
ES2429097T3 ES06824193T ES06824193T ES2429097T3 ES 2429097 T3 ES2429097 T3 ES 2429097T3 ES 06824193 T ES06824193 T ES 06824193T ES 06824193 T ES06824193 T ES 06824193T ES 2429097 T3 ES2429097 T3 ES 2429097T3
Authority
ES
Spain
Prior art keywords
tablet
solid dispersion
pharmaceutically acceptable
fused solid
acceptable excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06824193T
Other languages
English (en)
Spanish (es)
Inventor
Jong Soo Woo
Sang Wook Kim
Hong Gi Yi
Jae Kuk Ryu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Science Co Ltd
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd, Hanmi Holdings Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of ES2429097T3 publication Critical patent/ES2429097T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06824193T 2005-12-16 2006-12-18 Dispersión sólida que comprende un principio activo de bajo punto de fusión y comprimido para administración oral que la comprende Active ES2429097T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20050124386 2005-12-16
KR20050124386 2005-12-16
PCT/KR2006/005526 WO2007069874A1 (en) 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same

Publications (1)

Publication Number Publication Date
ES2429097T3 true ES2429097T3 (es) 2013-11-13

Family

ID=38163142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06824193T Active ES2429097T3 (es) 2005-12-16 2006-12-18 Dispersión sólida que comprende un principio activo de bajo punto de fusión y comprimido para administración oral que la comprende

Country Status (14)

Country Link
US (1) US20080292702A1 (enExample)
EP (1) EP1968542B1 (enExample)
JP (1) JP2009519326A (enExample)
CN (1) CN101330904B (enExample)
AU (1) AU2006325658B2 (enExample)
BR (1) BRPI0619868A8 (enExample)
CA (1) CA2633266C (enExample)
ES (1) ES2429097T3 (enExample)
IL (1) IL191804A0 (enExample)
NO (1) NO339674B1 (enExample)
NZ (1) NZ569813A (enExample)
RU (1) RU2403013C2 (enExample)
WO (1) WO2007069874A1 (enExample)
ZA (1) ZA200806138B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002731A (es) 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
KR101005391B1 (ko) * 2008-07-22 2010-12-30 한국콜마 주식회사 덱시부프로펜 함유 서방출성 시럽제 및 그의 제조방법
KR101067224B1 (ko) * 2008-07-22 2011-09-22 한국콜마 주식회사 이부프로펜 함유 서방출성 시럽제 및 그의 제조방법
CN101961306B (zh) * 2009-07-24 2011-11-09 北京化工大学 一种低熔点药物固体分散体的制备方法
CN102144982B (zh) * 2011-03-30 2012-12-12 江苏神龙药业有限公司 一种米诺膦酸片及其制备方法
CN102406940B (zh) * 2011-11-01 2013-07-03 温州大学 一种纳米级片状羧甲基淀粉钠在固体分散体中的应用
WO2013154511A1 (en) * 2012-04-13 2013-10-17 Mahmut Bilgic Film tablet formulations comprising dexibuprofen
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
JP6647902B2 (ja) * 2015-10-30 2020-02-14 株式会社ファンケル 徐放性顆粒剤
CN106265522A (zh) * 2016-08-30 2017-01-04 铜陵翔宇商贸有限公司 布洛芬‑pvp共沉淀物及其制备方法
JP7147262B2 (ja) * 2017-05-23 2022-10-05 大正製薬株式会社 固形製剤
JP7109255B2 (ja) * 2017-05-23 2022-07-29 ライオン株式会社 粉砕物の製造方法及び錠剤の製造方法
EP3658123A4 (en) * 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
RU2685294C1 (ru) * 2018-05-10 2019-04-17 Общество с ограниченной ответственностью "ДИНОН" (ООО "ДИНОН") Поглотитель, способ его приготовления (варианты) и способ удаления диоксида углерода из газовых смесей
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
CN117363320B (zh) * 2023-12-07 2024-02-13 黑龙江省鑫博鑫交通科技有限公司 一种公路用融雪剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56120616A (en) * 1980-02-27 1981-09-22 Kaken Pharmaceut Co Ltd Ibuprofen-containing granule, its preparation, and internal medicine comprising it
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
CH669523A5 (enExample) * 1986-06-25 1989-03-31 Mepha Ag
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE69739165D1 (de) * 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
RU2246294C2 (ru) * 1999-12-09 2005-02-20 Дзе Бутс Компани ПЛС Терапевтические средства
GB0113839D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
AU2006325658A1 (en) 2007-06-21
EP1968542A4 (en) 2010-06-02
CA2633266C (en) 2011-08-02
IL191804A0 (en) 2008-12-29
JP2009519326A (ja) 2009-05-14
HK1126671A1 (en) 2009-09-11
NO339674B1 (no) 2017-01-23
AU2006325658B2 (en) 2010-04-08
RU2403013C2 (ru) 2010-11-10
BRPI0619868A2 (pt) 2011-10-25
ZA200806138B (en) 2009-11-25
CA2633266A1 (en) 2007-06-21
BRPI0619868A8 (pt) 2016-06-07
NZ569813A (en) 2011-07-29
CN101330904B (zh) 2012-04-18
RU2008129041A (ru) 2010-01-27
EP1968542A1 (en) 2008-09-17
EP1968542B1 (en) 2013-08-14
NO20083151L (no) 2008-09-05
WO2007069874A1 (en) 2007-06-21
US20080292702A1 (en) 2008-11-27
CN101330904A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
ES2429097T3 (es) Dispersión sólida que comprende un principio activo de bajo punto de fusión y comprimido para administración oral que la comprende
JP5054000B2 (ja) イマチニブおよび放出遅延剤を含む医薬組成物
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
WO2007072908A1 (ja) 薬物含有ワックスマトリックス粒子の製造方法、該方法に使用されるエクストルーダー、及びシロスタゾールを含有する徐放性製剤
CN101631533B (zh) 含有西洛他唑的控释制剂及其制备方法
KR101122447B1 (ko) 신규 제제
KR20190137920A (ko) 엔잘루타미드를 함유하는 경구 투여용 의약 조성물
HK1214160A1 (zh) Cetp抑制剂的药物组合物
CA2899389C (en) Solid dispersion comprising amorphous cilostazol
AU2022383315B2 (en) Solid dispersion, preparation method therefor, and solid formulation containing same
CN120676932A (zh) 贝祖拉替尼制剂
TW202345810A (zh) 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
MX2008007665A (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
HK1126671B (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
HK1218618B (en) Solid dispersion comprising amorphous cilostazol